Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial.

Tavenier et al. published a study protocol for a triple-blind, randomized, placebo-controlled trial of low-dose fisetin (100 mg orally once daily for 7 weeks) in middle-aged and older adults. The primary outcome is the between-group difference in change of plasma soluble urokinase plasminogen activator receptor (suPAR), a marker of chronic inflammation, from baseline to week 7. This is a protocol paper only — no results have been reported. Fisetin remains under clinical investigation as a senolytic and anti-inflammatory agent; the trial will add to the limited human evidence base once completed.